New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Vor Biopharma

Contributing Author

Recent Articles by Vor Biopharma

Oct-03	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Sep-29	Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjogren's Disease Clinical Study at ACR Convergence 2025 VOR GlobeNewswire
Sep-23	Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer VOR GlobeNewswire
Sep-17	Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM VOR GlobeNewswire
Sep-12	Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum VOR GlobeNewswire
Sep-02	Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel VOR GlobeNewswire
Aug-27	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy VOR GlobeNewswire
Aug-26	Vor Bio to Participate in Upcoming Investor Conferences VOR GlobeNewswire
Aug-18	Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Aug-13	Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjogren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor VOR GlobeNewswire
Aug-04	Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer VOR GlobeNewswire
Jul-21	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors VOR GlobeNewswire
Jul-18	Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Jul-17	Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer VOR GlobeNewswire
Jul-10	Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer VOR GlobeNewswire
Jul-01	Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VOR GlobeNewswire
Jun-25	Vor Bio Announces $175 Million Private Placement VOR GlobeNewswire
Jun-25	Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset VOR GlobeNewswire
May-08	Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value VOR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.